AMRN - שולי רווח נקי amarincorp.com

Relative net sales profit demonstrates the financial stability of Amarin Corporation plc (AMRN). This trend is based on the sale of Vascepa through insurance funds and pharmacies for the therapy of hypertriglyceridemia. The company is currently shifting its strategic focus by developing B2B cooperation in China and Europe due to patent expirations. The value of -10.90 shows the current metric value, confirming the status of a brand that created a benchmark drug based on omega-3 fatty acids.
AMRN (Amarin Corporation plc): פילוחים אנליטיים ודוחות לפי אינדיקטורים

For the long-term investor, the reliability of Amarin Corporation plc (AMRN) is determined by its ability to maintain Vascepa's profitability amid generic expansion and European market adaptation. The net profit margin, reflecting the portion of final income from every dollar of revenue, allows for an assessment of cost management efficiency and overall financial stability through the company's commercial profit margin.